Showing the latest 10 filings. Sign in to filter or browse the full history.
10 of 89 filings·Updated 12 Aug 2026
Showing 10 of 89 filings.
12 Aug 20262 filings
Company UpdateInvestor Presentation

Symphony updates Corporate Presentation on website to meet SEBI LODR compliance

Regulatory Update

  • Updated Corporate Presentation uploaded on the company website under Corporate Governance.
  • Compliance with SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.
  • Update posted on August 12, 2026.
Filed 18:15View Source
Company UpdateGeneral

Symphony to hold media interaction with NDTV Profit on Aug 12, 2026

Media interaction schedule

  • Management to interact with NDTV Profit on Aug 12, 2026 to discuss business overview.
  • Details of the telecast to be posted on the company's website.
  • Date is subject to change; interaction may be postponed or cancelled.
Filed 11:17View Source
11 Aug 20261 filing
Company UpdateEarnings Call Transcript

Symphony Q1 FY27: standalone revenue ₹241 crore; margins steady; US/China growth offsets export headwinds.

Financial Performance

  • Standalone June quarter revenue ₹241 crore, EBITDA ₹30 crore, PAT ₹28 crore, vs ₹24 crore PAT last year.
  • India revenue grew 15%; modern trade grew over 100%; digital channels profitable.
  • June 30, 2026, standalone capital employed ₹73 crore; consolidated ₹206 crore.
  • Standalone ROCE 164%; return on net worth 22%.
  • Treasury ₹345 crore after repaying ₹225 crore of acquisition and working-capital loans.
  • Consolidated ROCE 67%; consolidated return on net worth 18%.
  • Interim dividend of ₹1 per share; total payout about ₹7 crore.
  • Exports declined on standalone due to geopolitical/shipping disruptions.
  • Consolidated BISP share about 48%; standalone BISP share trailing 12 months 23%.
  • Inventory normalized as of 30 June 2026; no inventory overhang.
  • Bonaire USA topline ₹36 crore; EBITDA ₹18 crore; PAT ₹17 crore.
  • IMPCO Mexico topline ₹54 crore; EBITDA ₹3 crore; PAT ₹1 crore.
  • GSK China topline ₹34 crore; EBITDA ₹6 crore; PAT ₹5 crore.
  • CTPL Australia revenue ₹27 crore; EBITDA −₹4 crore; PAT ₹36 crore due to one-time gain.

Operating Update

  • Modern trade and e-commerce together about one-third of India top line; general trade 60–65%.
  • Price hikes: household cooler segment unchanged; other segments price hikes 7–10%.
  • Costs elevated; margins likely to be impacted short term; some pass-through planned.
  • Bonaire USA growth driven by Air Force model; rebranded Indian SKUs.

Geography & Subsidiaries

  • Bonaire USA topline ₹36 crore; PAT ₹17 crore.
  • IMPCO Mexico topline ₹54 crore; EBITDA ₹3 crore; PAT ₹1 crore.
  • GSK China topline ₹34 crore; EBITDA ₹6 crore; PAT ₹5 crore.
  • CTPL Australia revenue ₹27 crore; EBITDA −₹4 crore; PAT ₹36 crore due to one-time gain.
  • CTPL Australia impairment history; no further capital deployment planned.

Balance Sheet & Cash Flow

  • Standalone capital employed ₹73 crore; consolidated ₹206 crore.
  • Treasury ₹345 crore after repayments; acquisition loan and working-capital loans ₹225 crore.
  • Interim dividend declared ₹1 per share (₹7 crore total).

Outlook & Guidance

  • Near-term margins likely to be pressured; partial pass-through of elevated costs.
  • US revenue in current quarter; next two quarters expected to be muted.
  • GSK China momentum to continue; exports dependent on orders.
  • No further capital deployment in Australia.

Q&A Highlights

  • Exact split of modern trade vs GT not disclosed; modern trade around one-third; GT about 60–65%.
  • 7–10% price hikes already taken in non-household segments; further hikes planned.
  • US market patchy; summer boosts; growth likely to continue but seasonal.
  • Air Force model major driver for Bonaire USA.
  • GSK China momentum; exports dependent on orders.
  • Australia strategy: no new products; conserve capital.
  • ROW growth outlook: Mexico and USA summers strong; 2027 unlikely to be mild.

Risks & Watchpoints

  • Middle East export disruptions; costs rise; buyer sentiment cautious.
  • Export shipments resumed; logistics disruptions persist; geopolitical uncertainties affecting orders.
  • US seasonality limits near-term revenue visibility; macro factors remain a risk.
Filed 16:34View Source
10 Aug 20262 filings
Company UpdateAnalyst / Investor Meet

Symphony to participate in Equirius and Emkay investor conferences on Aug 13–14, 2026

Meeting Details

  • Aug 13–14, 2026; One-on-One/Group meetings; physical in Mumbai; times not specified.

Participants

  • Company management to participate in investor/analyst meetings.

Event / Organizer

  • Equirius Annual India Conference 2026; Emkay Confluence 2026.

Purpose

  • Interaction with institutional investor(s) and analyst(s).

Additional Notes

  • Presentation already posted on Symphony's website.
Filed 16:19View Source
Company UpdateAnalyst / Investor Meet

Symphony to participate in Equirius and Emkay investor conferences in Mumbai on Aug 13–14, 2026

Meeting Details

  • Aug 13, 2026: Equirius Annual India Conference 2026; One-on-One / Group; Mumbai
  • Aug 14, 2026: Emkay Confluence 2026: India – Full Throttle Ahead; One-on-One / Group; Mumbai

Additional Notes

  • Presentation for the meetings is available on the company website.
Filed 16:19View Source
5 Aug 20262 filings
Company UpdateNewspaper Publication

Submission of Newspaper Clippings of Publication of Financial Results

Filed 14:00View Source
Company UpdateCopy of Newspaper Publication

Submission of newspaper clippings of publication of finncial results

Filed 14:00View Source
28 Jul 20262 filings
Company UpdateNewspaper Publication

Submission of Newspaper Clippings

Filed 10:26View Source
Company UpdateCopy of Newspaper Publication

Submission of Newspaper clippings

Filed 10:23View Source
27 Jul 20261 filing
Corp. ActionRecord Date

Symphony Ltd fixes Aug 11, 2026 as record date for 1st interim dividend

Dividend record date

  • Record date set for payment of 1st interim dividend for FY 2026-27.
  • Security type: Equity shares; Book closure: not mentioned.
  • Record date: 11 August 2026; entitlement to shareholders as on Aug 11, 2026.
  • Subject to board approval in meeting on 4 August 2026.
  • Entitlement to beneficial owners as per depository records and members as on Aug 11, 2026.
  • Dividend amount not disclosed.
Filed 11:12View Source
Showing 10 of 89 filings